Special Issue on Obstructive Sleep Apnea: A Systemic Disease

Submission Deadline: Feb. 28, 2016

  • Special Issue Editor
    • Aliae AR Mohamed-Hussein
      Chest Department, Assiut University Hospitals, Assiut, Egypt
    • Klaus Dulhoff
      Pulmonology Department, Medical University of Lubeck, Lubeck, Germany
    • Tenor Henning Koth
      Pulmonology Department, Medical University of Lubeck, Lubeck, Germany
    • Andreas Rembert Koczulla
      Pulmonology Department, Marburg University, Marburg, Germany
    • Roland Buhl
      Pulmonary Department, Mainz University Hospital, Mainz, Germany
    • Ayman Khairy
      Cardiology Department, Assiut University Hospitals, Assiut, Egypt
    • Sherifa Hamed
      Department of Neurology and Psychiatry, Assiut University Hospital, Assiut, Egypt
    • Hossam Gendi
      Essex Cardiac Center, Princess Alexandra Hospital, London, UK
    • John Moxham
      Physiology Department, Kings College London, London, UK
    • Micheal Polkey
      Physiology Department, Imperial College London, London, UK
    • Yoshino Ichiro
      Pulmonology Department, Chiba University, Chiba, Japan
    • Jafar Al-Sharab
      Northwestern State University, Las Vegas, Nevada, USA
    • Mohammed Obeidat
      Jordan University of Science and Technology, Amman, Jordan
    • Obair Siddiqui
      LG Electronics Inc., Detroit, Michigan, USA
  • Introduction

    Obstructive sleep apnea syndrome (OSAS) is a highly prevalent sleep disorder, characterized by repeated disruptions of breathing during sleep. This disease has many potential consequences including excessive daytime sleepiness, neurocognitive deterioration, endocrinologic and metabolic effects, and decreased quality of life. Metabolic syndrome is another highly prevalence emerging public health problem that represents a constellation of cardiovascular risk factors. Each single component of the cluster increases the cardiovascular risk, but the combination of factors is much more significant. It has been suggested that the presence of OSAS may increase the risk of developing some metabolic syndrome features. Moreover, OSAS patients are at an increased risk for vascular events, which represent the greatest morbidity and mortality of all associated complications.

    Although the etiology of OSAS is uncertain, intense local and systemic inflammation is present. A variety of phenomena are implicated in this disease such as modifications in the autonomic nervous system, hypoxemia–reoxygenation cycles, inflammation, and coagulation–fibrinolysis imbalance. OSAS patients also present increased levels of certain biomarkers linked to endocrine-metabolic and cardiovascular alterations among other systemic consequences.

    The Aim of this Special issue is to clarify that OSAS is more than a local abnormality, and it should be considered a systemic disease.

  • Guidelines for Submission

    Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.

    Papers should be formatted according to the guidelines for authors (see: http://www.sjpublichealth.org/submission). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.

  • Published Papers

    The special issue currently is open for paper submission. Potential authors are humbly requested to submit an electronic copy of their complete manuscript by clicking here.

Browse journals by subject